Equity Financings. LeukoSite agrees that, prior to the conversion of the shares of LeukoSite Series A Preferred Stock into shares of LeukoSite Common Stock, LeukoSite will not issue shares of LeukoSite Common Stock or LeukoSite Preferred Stock in an equity financing (other than in connection with a public offering pursuant to a registration statement) without either (a) obtaining irrevocable binding commitments or proxies from each purchaser in such equity financing or such lesser number of such purchasers as may be required to obtain stockholder approval in favor of (i) the conversion of the shares of LeukoSite Series A Preferred Stock issued pursuant to the Merger into shares of LeukoSite Common Stock and (ii) the issuance of any other Merger Shares issuable pursuant to this Agreement in the form of LeukoSite Common Stock, or (b) the prior written consent of the holders of a majority of the outstanding shares of LeukoSite Series A Preferred Stock.
Equity Financings. Upon the consummation of any Financing by the Borrower or any Subsidiary constituting a sale or issuance of any Disqualified Stock or Equity Interests thereby (other than in connection with stock issued within thirty (30) days prior to or within thirty (30) days following the consummation of a Permitted Acquisition, to the extent that the Borrower or such Subsidiary intends to fund such proposed Permitted Acquisition with the Net Cash Proceeds of such stock and so indicates to the Administrative Agent in writing prior to its issuance or prior to the consummation of the Permitted Acquisition, whichever is earlier, and, in any case, solely to the extent the Net Cash Proceeds thereof are in fact utilized to fund such Permitted Acquisition), within three (3) Business Days after the Borrower's or any of its Subsidiaries' receipt of any Net Cash Proceeds from such Financing (or within thirty (30) days following the issuance of any stock described in the preceding parenthetical that has been issued prior to the consummation of a proposed Permitted Acquisition if the related Permitted Acquisition has not occurred as of such thirtieth (30th) day), the Borrower shall make a mandatory prepayment of the Obligations in an amount equal to fifty percent (50%) of such Net Cash Proceeds (it being understood that if stock described in the second preceding parenthetical has been issued within thirty (30) days following the consummation of a Permitted Acquisition, the Borrower or such Subsidiary shall be required to fund the related Permitted Acquisition, or make a mandatory prepayment of the Obligations as otherwise required by this clause (c), within three (3) Business Days after the Borrower's or any of its Subsidiaries' receipt of any Net Cash Proceeds from such Financing).
Equity Financings. From the date of this Agreement until the earlier of the termination of this Agreement pursuant to ARTICLE 7 or the Effective Time, Parent and the Company shall not, without the prior written consent of the other party, issue, or enter into any agreement to issue, any shares of capital stock or any other securities convertible into, or any rights, warrants or options to acquire, any such shares, securities or convertible securities or any other securities or equity equivalents in connection with a capital raising transaction.
Equity Financings. (a) For so long as the Strategic Investor’s Percentage is at least 8%, in the event that the Company proposes to issue Common Shares or Convertible Securities, including convertible debt securities (collectively, “Equity Securities”) directly or indirectly, for cash or cash equivalents (an “Equity Financing”), other than the issue of Equity Securities (i) in respect of which the Top-Up Right (as defined below) would be applicable; or (ii) pursuant to a rights offering (“Rights Offering”) by the Company that is open to all Shareholders:
Equity Financings. Please provide the following information regarding the Borrower’s equity financing: Date of Last Round Raised: Has there been any new financing since the last Compliance Certificate submitted? YES / NO If “YES” please complete information below and attach a copy of the Capitalization Table Date Closed: Series: Per Share Price: $ Amount Raised: Post Money Valuation: Any stock splits since date of last report? YES / NO If yes, please provide any information on stock splits which would affect valuation: Any dividends since date of last report? YES / NO If yes, please provide any information on dividends which would affect valuation: Any unusual terms? (ie. Anti-dilution, multiple preference, etc.) If yes, please explain:
Equity Financings. Vigilant will apply the proceeds of any equity financing greater than $500,000 toward the repayment of the Notes as set forth in Section 9.a. of the Secured Agreements. Vigilant will apply the proceeds of any equity financing greater than $750,000 toward the repayment of the SalAero Note as set forth in Section 9.a. of the SalAero Amendment to Secured Promissory Note and Security Agreement dated October 17, 2018 (the “SalAero Secured Agreement”).
Equity Financings. Upon the consummation of any Financing by the Parent, any Borrower or any Subsidiary constituting a sale or issuance of any Disqualified Stock or Equity Interests (other than in connection with stock issued to fund Permitted Acquisitions) thereby, within three (3) Business Days after the Parent's the Borrowers' or any of their respective Subsidiaries' receipt of any Net Cash Proceeds from such Financing, the Borrowers shall make a mandatory prepayment of the Obligations in an amount equal to fifty percent (50%) of such Net Cash Proceeds.
Equity Financings. Prior to the thirty (30) day anniversary of the Effective Date (plus one additional day for each Trading Day following the Effective Date of any Registration Statement during which either (1) a Registration Statement is not effective for the resale of all Underlying Shares or (2) the prospectus forming a portion of the Registration Statement is not available for the resale of all Underlying Shares) (the “Lockup Date”), the Company shall not, without the written consent of Investors representing at least 75% of the aggregate principal amount of all Notes then outstanding, issue any Common Stock or Common Stock Equivalents that, in each case, are granted rights to have such Common Stock or Common Stock Equivalents filed with the Commission for the purpose of registering the resale of such Common Stock or Common Stock Equivalents before the Lockup Date; provided, however, that no such consent shall be required for the issuance by the Company of any Common Stock or Common Stock Equivalents in connection with a Strategic Transaction; and provided, further, that if one or more Registration Statements has previously been declared effective as to 75% of the Underlying Shares, then no such consent shall be required for the issuance by the Company of any Common Stock or Common Stock Equivalents that occurs simultaneously with or following the effectiveness of the Registration Statement which results in all Underlying Shares being registered and a prospectus forming a portion of a Registration Statement being available for the resale of all Underlying Shares.
Equity Financings. Including the proceeds from the sale of Shares pursuant to this Agreement, the Company shall have received a minimum of $24,000,000 in equity financing since September 30, 2000. This Agreement may be terminated by the Purchaser if the Closing has not transpired by the 75th day after the Effective Date for reasons other than a breach of this Agreement by the Purchaser.
Equity Financings. Any issuance of shares of capital stock by the Company that CPK would have a right to subscribe for or purchase a portion thereof pursuant to Section 6 below.
